UY27221A1 - Composición que comprende adyuvante prebiótico para disminuir procesos inflamatorios y activación anormal de parámetros inespecíficos inmunitarios - Google Patents

Composición que comprende adyuvante prebiótico para disminuir procesos inflamatorios y activación anormal de parámetros inespecíficos inmunitarios

Info

Publication number
UY27221A1
UY27221A1 UY27221A UY27221A UY27221A1 UY 27221 A1 UY27221 A1 UY 27221A1 UY 27221 A UY27221 A UY 27221A UY 27221 A UY27221 A UY 27221A UY 27221 A1 UY27221 A1 UY 27221A1
Authority
UY
Uruguay
Prior art keywords
composition
inflammatory processes
parameters
inespective
immune
Prior art date
Application number
UY27221A
Other languages
English (en)
Inventor
Florence Rochat
Eduardo Schiffrin
Yves Guigoz
Original Assignee
Nestle Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8180054&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY27221(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nestle Sa filed Critical Nestle Sa
Publication of UY27221A1 publication Critical patent/UY27221A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
    • A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
    • A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/163—Sugars; Polysaccharides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
    • A23K50/42—Dry feed
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
    • A23K50/48—Moist feed
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Animal Husbandry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Birds (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Physiology (AREA)
  • Pediatric Medicine (AREA)
  • Transplantation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Fodder In General (AREA)
  • Feed For Specific Animals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se relaciona con una composición que comprende un adyuvante prebiótico para disminuir procesos inflamatorios al mejorar la hemeostasis de parámetros inmunitarios inespecíficos y de subplobaciones de linfocitos. También se relaciona con el uso de una formulación coadyuvante prebiótico en la elaboración de una composición de medicamento o un alimento para mascotas, para disminuir procesos inflamatorios o actividad anormal de parámetros inmunitarios inespecíficos, tales como fagocitos o ambas cosas.
UY27221A 2001-03-22 2002-03-21 Composición que comprende adyuvante prebiótico para disminuir procesos inflamatorios y activación anormal de parámetros inespecíficos inmunitarios UY27221A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01201091A EP1243273A1 (en) 2001-03-22 2001-03-22 Composition comprising a prebiotic for decreasing infammatory process and abnormal activation of non-specific immune parameters

Publications (1)

Publication Number Publication Date
UY27221A1 true UY27221A1 (es) 2002-08-30

Family

ID=8180054

Family Applications (1)

Application Number Title Priority Date Filing Date
UY27221A UY27221A1 (es) 2001-03-22 2002-03-21 Composición que comprende adyuvante prebiótico para disminuir procesos inflamatorios y activación anormal de parámetros inespecíficos inmunitarios

Country Status (14)

Country Link
US (1) US8092608B2 (es)
EP (2) EP1243273A1 (es)
JP (1) JP4456329B2 (es)
CN (1) CN1738595B (es)
AR (1) AR033439A1 (es)
AT (1) ATE350045T1 (es)
CA (1) CA2442053C (es)
DE (1) DE60217319T3 (es)
EA (1) EA006441B1 (es)
ES (1) ES2278021T5 (es)
PE (1) PE20020986A1 (es)
UY (1) UY27221A1 (es)
WO (1) WO2002076471A1 (es)
ZA (1) ZA200308189B (es)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19836339B4 (de) 1998-08-11 2011-12-22 N.V. Nutricia Kohlenhydratmischung
CA2478991C (en) 2002-03-13 2015-06-30 Natarajan Ranganathan Compositions and methods for augmenting kidney function
EP1350435B1 (en) 2002-04-05 2010-12-22 Societe Des Produits Nestle S.A. Compositions and methods for promoting lipid assimilation in pets
US20090022852A1 (en) * 2002-06-21 2009-01-22 Dnp Canada Inc. Liquid Compositions Comprising Non-Digestible Oligosaccharides and Green Tea Catechins
AU2003245156A1 (en) * 2002-06-21 2004-01-06 Canacure Corporation Liquid compositions comprising non-digestible oligosaccharides and green tea catechins, method and uses thereof
PT1656449E (pt) 2003-08-21 2009-07-27 Monsanto Technology Llc Dessaturases dos ácidos gordos a partir de prímulas
US7118772B2 (en) * 2003-09-18 2006-10-10 General Mills, Inc. Inulin infused fruit and method of preparation
US20050119222A1 (en) * 2003-12-01 2005-06-02 The Iams Company Compositions comprising fermentable fiber which are adapted for use by a companion animal and kits and methods of their use
NO320546B1 (no) * 2003-12-12 2005-12-19 Nova Biotics As Prebiotiske kombinasjonsprodukter
US8877178B2 (en) 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
US20050158294A1 (en) 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
EP2902021B1 (en) * 2004-04-16 2018-11-14 Monsanto Technology LLC Expression of fatty acid desaturases in corn
EP1597978A1 (en) 2004-05-17 2005-11-23 Nutricia N.V. Synergism of GOS and polyfructose
US8252769B2 (en) 2004-06-22 2012-08-28 N. V. Nutricia Intestinal barrier integrity
US7862808B2 (en) * 2004-07-01 2011-01-04 Mead Johnson Nutrition Company Method for preventing or treating respiratory infections and acute otitis media in infants using Lactobacillus rhamnosus LGG and Bifidobacterium lactis Bb-12
WO2006012536A2 (en) 2004-07-22 2006-02-02 Ritter Andrew J Methods and compositions for treating lactose intolerance
FR2877844B1 (fr) * 2004-11-18 2008-05-09 United Pharmaceuticals Sa Sa Composition contenant un probiotique destinee a l'alimentation infantile chez des sujets souffrant de diarrhees
US7303745B2 (en) * 2005-04-15 2007-12-04 Bristol-Myers Squibb Company Method for preventing or treating the development of respiratory allergies
BRPI0611492B1 (pt) 2005-05-31 2021-10-13 Mars, Incorporated Bifidobactéria probiótica felina
CA2609617C (en) 2005-05-31 2014-07-08 The Iams Company Feline probiotic lactobacilli
US7572474B2 (en) 2005-06-01 2009-08-11 Mead Johnson Nutrition Company Method for simulating the functional attributes of human milk oligosaccharides in formula-fed infants
HUP0500582A1 (hu) * 2005-06-13 2007-08-28 Csaba Jozsef Dr Jaszberenyi Szinergetikus élettani hatású élelmiszerek, élelmiszer-adalékok és táplálék-kiegészítõk vagy takarmányadalékok
US8075934B2 (en) * 2008-10-24 2011-12-13 Mead Johnson Nutrition Company Nutritional composition with improved digestibility
US8287931B2 (en) * 2005-06-30 2012-10-16 Mead Johnson Nutrition Company Nutritional composition to promote healthy development and growth
ES2561584T3 (es) 2005-09-28 2016-02-29 Nordisk Rebalance A/S Tratamiento del SII usando como efectores de tratamiento tanto bacterias probióticas como cereales fermentados
WO2007046441A1 (ja) 2005-10-18 2007-04-26 Kao Corporation ペットフード
MY144556A (en) * 2005-10-24 2011-09-30 Nestec Sa Dietary fiber formulation and method of administration
RU2448720C2 (ru) 2006-03-07 2012-04-27 Нестек С.А. Синбиотическая смесь
JP5689601B2 (ja) * 2006-12-11 2015-03-25 デュポン ニュートリション バイオサイエンシーズ エーピーエス 組成物
PL2124966T3 (pl) 2007-02-01 2016-01-29 Iams Europe B V Sposób zmniejszania reakcji zapalnej i stresu u ssaków za pomocą antymetabolitów glukozy, awokado lub ekstraktów awokado
US9771199B2 (en) * 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
US9232813B2 (en) * 2008-07-07 2016-01-12 The Iams Company Probiotic supplement, process for making, and packaging
CA2735659C (en) * 2008-09-11 2013-10-29 The Iams Company Animal feed kibble with protein-based core and related methods
US8986769B2 (en) * 2008-10-24 2015-03-24 Mead Johnson Nutrition Company Methods for preserving endogenous TGF-β
US8425955B2 (en) 2009-02-12 2013-04-23 Mead Johnson Nutrition Company Nutritional composition with prebiotic component
EP2400839B1 (en) 2009-02-24 2016-09-07 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
US8293264B2 (en) * 2009-05-11 2012-10-23 Mead Johnson Nutrition Company Nutritional composition to promote healthy development and growth
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
EP2498626B1 (en) * 2009-11-12 2015-06-17 Nestec S.A. Nutritional composition for promoting gut microbiota balance and health
EP3202406A1 (en) 2010-04-28 2017-08-09 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
BR112013004194A2 (pt) * 2010-08-25 2016-05-10 Tate & Lyle Ingredients produto simbiótico
DE102011052687A1 (de) 2011-08-12 2013-02-14 Lohmann Animal Health Gmbh Verwendung von Antioxidantien
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
WO2014007606A1 (en) 2012-07-05 2014-01-09 N.V. Nutricia Product for use in the prophylactic or therapeutic treatment of a negative emotion or introvert behaviour
GB201312713D0 (en) * 2013-03-22 2013-08-28 Weaver Connie M Uses of soluble corn fibre for increasing colonic bacteria populations and increasing mineral absorption
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
DK3065748T3 (da) 2014-12-23 2018-01-29 4D Pharma Res Ltd En bacteroides thetaiotaomicron stamme og dens anvendelse til reduktion af inflammation
SG11201704814SA (en) 2014-12-23 2017-07-28 4D Pharma Res Ltd Pirin polypeptide and immune modulation
PT3360559T (pt) 2015-06-15 2020-01-06 4D Pharma Res Ltd Composições compreendendo estirpes bacterianas
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
AU2016278067B2 (en) 2015-06-15 2022-09-22 Cj Bioscience, Inc. Compositions comprising bacterial strains
SG10201912326QA (en) 2015-06-15 2020-02-27 4D Pharma Res Ltd Compositions comprising bacterial strains
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB2561748B (en) 2015-11-20 2019-05-08 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
KR102010207B1 (ko) 2016-03-04 2019-08-12 4디 파마 피엘씨 세균 균주를 포함하는 조성물
TW201821093A (zh) 2016-07-13 2018-06-16 英商４Ｄ製藥有限公司 包含細菌菌株之組合物
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
CN109414037A (zh) 2016-12-15 2019-03-01 雀巢产品技术援助有限公司 调节伴侣动物中的细菌的组合物和方法
WO2018215758A1 (en) 2017-05-22 2018-11-29 4D Pharma Research Limited Compositions comprising bacterial strains
WO2018215782A1 (en) 2017-05-24 2018-11-29 4D Pharma Research Limited Compositions comprising bacterial strain
JP6884889B2 (ja) 2017-06-14 2021-06-09 フォーディー ファーマ リサーチ リミテッド４Ｄ Ｐｈａｒｍａ Ｒｅｓｅａｒｃｈ Ｌｉｍｉｔｅｄ 細菌株を含む組成物
PL3804737T3 (pl) 2017-06-14 2022-09-12 4D Pharma Research Limited Kompozycje zawierające szczepy bakteryjne
EP3735134A4 (en) * 2018-01-04 2022-01-19 White Dog Labs, Inc. METHOD AND COMPOSITION FOR IMPROVING ANIMAL HEALTH COMPRISING ORGANIC CELLS CONSISTING OF STEM IN THE ORDER CLOSTRIDIALES
CN110279117A (zh) * 2018-03-19 2019-09-27 医迈霖科技公司 一种益生菌冻干食品
CN112616925A (zh) * 2020-12-30 2021-04-09 光明乳业股份有限公司 一种双蛋白发酵乳及其制备方法
CN114099408A (zh) * 2021-09-23 2022-03-01 仙婷(广州)科技研发有限公司 一种含有益生元、益生菌和后生元的组合物及其制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5531989A (en) * 1994-10-28 1996-07-02 Metagenics, Inc. Immunoglobulin and fiber-containing composition for human gastrointestinal health
PT820292E (pt) † 1995-04-05 2003-06-30 Abbott Lab Inibicao de infeccoes por c. difficile com oligossacaridos nao digeriveis
US5849324A (en) * 1995-07-10 1998-12-15 Abbott Laboratories Use of indigestible oligosaccharides to reduce the incidence of otitis media in humans
JPH11504049A (ja) * 1996-02-14 1999-04-06 ザ、プロクター、エンド、ギャンブル、カンパニー ツツジ科の植物種より由来する物質および乳酸バクテリア成長因子を含む泌尿生殖器および腸の疾患用の組成物
ATE169456T1 (de) * 1996-12-23 1998-08-15 Sitia Yomo Spa Lyophilisierte, lebende bakerien enthaltende nahrungszusammensetzung
FI107014B (fi) * 1997-07-25 2001-05-31 Oriola Oy Terveysravintovalmiste
US6203797B1 (en) * 1998-01-06 2001-03-20 Stephen C. Perry Dietary supplement and method for use as a probiotic, for alleviating the symptons associated with irritable bowel syndrome
US6130244A (en) * 1998-02-25 2000-10-10 Abbott Laboratories Product and method to reduce stress induced immune suppression
CN1273039A (zh) * 1999-05-06 2000-11-15 四川禾嘉生物制品有限公司 含有生物活性成分的饲料添加剂
CA2281463A1 (en) * 1999-08-26 2001-02-26 Stanley H. Zlotkin Composition comprising micronutrients in combination with prebiotics, probiotics, and synbiotics
DE19958985A1 (de) * 1999-12-07 2001-06-13 Nutricia Nv Oligosaccharidmischung
EP1125507A1 (en) † 2000-02-15 2001-08-22 Tiense Suikerraffinaderij N.V. (Raffinerie Tirlemontoise S.A.) Inulin products with improved nutritional properties
CA2400737C (en) * 2000-02-17 2010-12-14 Jeffrey L. Wilson Nutritional formulation containing prebiotic substances
US20020044988A1 (en) † 2000-08-22 2002-04-18 Fuchs Eileen C. Nutritional composition and method for improving protein deposition
EP1372412A2 (en) † 2001-03-09 2004-01-02 Societe Des Produits Nestle S.A. Composition improving age-related physiological deficits and increasing longevity
JP3975266B2 (ja) * 2002-05-24 2007-09-12 独立行政法人産業技術総合研究所 細胞培養装置

Also Published As

Publication number Publication date
ES2278021T3 (es) 2007-08-01
EP1383514B1 (en) 2007-01-03
ES2278021T5 (es) 2019-05-13
DE60217319D1 (de) 2007-02-15
EA006441B1 (ru) 2005-12-29
DE60217319T2 (de) 2007-10-04
CN1738595A (zh) 2006-02-22
CA2442053A1 (en) 2002-10-03
AR033439A1 (es) 2003-12-17
PE20020986A1 (es) 2003-01-02
CA2442053C (en) 2012-07-10
WO2002076471A1 (en) 2002-10-03
JP2004529910A (ja) 2004-09-30
DE60217319T3 (de) 2019-04-18
CN1738595B (zh) 2011-01-12
EP1383514A1 (en) 2004-01-28
EP1243273A1 (en) 2002-09-25
EP1383514B2 (en) 2018-12-19
ZA200308189B (en) 2005-03-30
US20040219157A1 (en) 2004-11-04
ATE350045T1 (de) 2007-01-15
JP4456329B2 (ja) 2010-04-28
US8092608B2 (en) 2012-01-10
EA200301044A1 (ru) 2004-04-29

Similar Documents

Publication Publication Date Title
UY27221A1 (es) Composición que comprende adyuvante prebiótico para disminuir procesos inflamatorios y activación anormal de parámetros inespecíficos inmunitarios
ECSP077316A (es) Compuestos imidazo-3-il-amina bicíclicos sustituidos
ECSP034916A (es) Oxazolidinonas substituidas para terapia de combinacion
AR058098A1 (es) Derivados de acidos dicarboxilicos y su uso
CY1113449T1 (el) Αντι-ιικες συνθεσεις που περιλαμβανουν γερανιολη και καρβονη
ECSP067043A (es) Derivados de pirrolotriazina útiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogénesis
AR090491A1 (es) Tratamiento de la esclerosis multiple con una combinacion de laquinimod y fumarato de dimetilo
BR112013026032A2 (pt) composições nutricionais incluindo ácidos graxos de cadeia ramificada para cicatrização de ferida
BRPI0515316A (pt) compostos de imidazoquinolina
CO6410279A2 (es) Composición farmacéutica que comprende derivados de glucopiranosil difenilmetano, forma farmacéutica de la misma, procedimiento para su preparación y usos de la misma para el control glucémico mejorado en un paciente.
WO2010000877A3 (en) Formulation with irritation reducing action comprising bisabolol and [6]-paradol
CL2012002497A1 (es) Compuestos derivados de imidazopirimidina,sustituidos, inhibidores de la pde10a; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento o prevencion de trastornos psicoticos, esquizofrenia, enfermedad de parkinson, esclerosis multiple, entre otras.
CL2008003473A1 (es) Compuestos derivados de fenilpiperidina sustituidos por heterociclos; procedimiento de preparacion; composicion farmaceutica que lo comprende; y uso en el tratamiento del trastorno cardiovasculares, tromboembolicos y tumorales; usos in vitro.
HN2002000275A (es) Derivados de 1,8 naftiridina y su uso para el tratamiento de diabetes y trastornos relacionados
ECSP099620A (es) Derivados de ciclohexano espirociclico
JO2721B1 (en) Derivatives of artemisia plant and its preparations and therapeutic applications
TW200942524A (en) Novel aminomethyl benzene derivatives
WO2007057748A3 (en) Use of colostrum for the prophylaxis of influenza syndromes
BR112012007798A2 (pt) microcápsulas estáveis e composição para aplicação tópica e método para a preparação de microcápsulas
MXPA05013016A (es) Gaboxadol para el tratamiento de la depresion y otros trastornos afectivos.
NO20074780L (no) Heterocyklylamidsubstituerte imidazoler
WO2005076761A3 (en) Composition for preenting a cold
WO2007150008A3 (en) Polypeptides from african swine virus as vaccines for preventive and therapeutic use
TR201004464A2 (tr) Kemik erimesi için formülasyon.
DE502005006427D1 (de) Substituierte azachinazoline mit antiviraler wirkung

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20141205